Prazosin Hydrochloride (Extended-Release GITS) [3.33] — Monograph & Safety

1. Clinical & Scientific Overview

Prazosin Hydrochloride (Extended-Release GITS) (TIP-MED-000033, Reference Code [3.33]) is classified under Cardiovascular & Antithrombotic Medicines (Ch 03) as a Selective Postsynaptic Alpha-1 Adrenoceptor Blocker (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Lanoxin (GSK), Dixogin (Ipca)

Representative Indian Market Examples (Edition 2.7 Ch 03 [3.33], p. 37): Minipress XL (Pfizer), Prazopress XL (Sun) — Strengths & Dosage Forms: Extended-Release Osmotic (XL/GITS) Tablets: 2.5 mg, 5 mg; Immediate-Release (IR) Tablets: 1 mg, 2 mg (for scorpion sting autonomic storm)

Dosage Forms & Available Strengths:
Extended-Release Osmotic (XL/GITS) Tablets: 2.5 mg, 5 mg; Immediate-Release (IR) Tablets: 1 mg, 2 mg (for scorpion sting autonomic storm)

Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Selective Postsynaptic Alpha-1 Adrenoceptor Blocker (Schedule H) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Selective Postsynaptic Alpha-1 Adrenoceptor Blocker (Schedule H) for Resistant hypertension (4th/5th-line add-on, especially in CKD where it is renally neutral), HTN with BPH; IR Prazosin is the specific physiological antidote for Indian Red Scorpion (Mesobuthus tamulus) sting!.

4. Therapeutic Indications & Evidence-Supported Uses

Resistant hypertension (4th/5th-line add-on, especially in CKD where it is renally neutral), HTN with BPH
IR Prazosin is the specific physiological antidote for Indian Red Scorpion (Mesobuthus tamulus) sting!

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Resistant HTN: Start 2.5–5 mg XL PO OD (at bedtime initially), titrate to 5–10 mg BD (Max 20 mg/day). Scorpion Sting: 250–500 mcg IR PO q3–6h

Administration & Meal Timing: Swallow XL tablets WHOLE with water; NEVER crush, chew, or divide XL osmotic tablets! | Bedtime (especially first dose!) or Morning & Bedtime (BD)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.

Metabolism & Biotransformation:
Renal: 100% hepatically cleared — NO dose adjustment needed in severe CKD or dialysis (major staple in Indian nephrology OPDs!). Hepatic: Start low in cirrhosis

Elimination & Renal Adjustment:
Renal: 100% hepatically cleared — NO dose adjustment needed in severe CKD or dialysis (major staple in Indian nephrology OPDs!). Hepatic: Start low in cirrhosis

Hepatic Impairment Considerations:
Renal: 100% hepatically cleared — NO dose adjustment needed in severe CKD or dialysis (major staple in Indian nephrology OPDs!). Hepatic: Start low in cirrhosis

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:

FIRST-DOSE SYNCOPE PHENOMENON: Can cause precipitous orthostatic hypotension and fainting within 30–90 minutes of the first dose; caution in cataract surgery (Intraoperative Floppy Iris Syndrome [IFIS])

Key Clinical Precautions: Renal: 100% hepatically cleared — NO dose adjustment needed in severe CKD or dialysis (major staple in Indian nephrology OPDs!). Hepatic: Start low in cirrhosis

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:

Postural dizziness, orthostatic hypotension, headache, drowsiness, nasal congestion, palpitations, priapism (rare)
First-dose syncope with falls/fractures, severe hypotension when combined with PDE-5 inhibitors (Sildenafil/Tadalafil) or high-dose diuretics

Serious / Dose-Limiting Adverse Effects:

Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

PDE-5 inhibitors (Sildenafil, Tadalafil) cause profound hypotension (separate by >=6h and use lowest dose); Beta-blockers and CCBs enhance first-dose hypotensive effect

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

Patient Counselling Checklist: Take the very first tablet while in bed at night to prevent fainting; rise slowly from bed; inform eye surgeon before cataract surgery; empty ghost tablet shell in stool is normal
Meal & Clock Timing Instruction: Swallow XL tablets WHOLE with water; NEVER crush, chew, or divide XL osmotic tablets! (Bedtime (especially first dose!) or Morning & Bedtime (BD))
Missed Dose Protocol: Take same day if remembered; if missed for >=2–3 days, re-initiate at bedtime to avoid first-dose syncope
Geriatric Dispensing Pearl: High risk of orthostatic falls in older adults (AGS Beers 2023) — avoid as routine 1st/2nd-line HTN monotherapy; reserve for resistant CKD HTN

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Extended-Release Osmotic (XL/GITS) Tablets: 2.5 mg, 5 mg; Immediate-Release (IR) Tablets: 1 mg, 2 mg (for scorpion sting autonomic storm)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.33] (p. 37)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

13. Related Reference Monographs, Educational Guides & Visual Concept

💊 Related Pharmacological / Category Profiles

[3.35] Methyldopa — Centrally Acting Alpha-2 Adrenoceptor Agonist Prodrug (Schedule H
[3.36] Sacubitril + Valsartan (ARNI) — Angiotensin Receptor–Neprilysin Inhibitor (Schedule H)
[3.37] Eplerenone — Selective Mineralocorticoid (Aldosterone) Receptor Antagonist — M
[3.38] Indapamide (Immediate & Sustained Release) — Thiazide-Like Sulfonamide Diuretic & Vasodilator (Schedule H)

📚 Related Knowledge Hub Educational Articles

Receptor Pharmacodynamics & Mechanism of Action Illustration

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback